By Product Type
By Research Area
Breakthroughs in molecular biology during the 20th century to write, edit, and erase DNA created new possibilities for medicine. A successful realization of this potential is the use of a tractable living system to make an active human protein. A notable early example was the use of E. coli by Genentech to make recombinant insulin (1).
As biology and medicine have changed, so too have the needs of recombinant proteins. For activity, many proteins require glycosylation and processing that is only available in eukaryotic systems. This led to the development of insect and Chinese hamster ovary (CHO) cells as recombinant protein producers.
As science and medicine have progressed, so these systems have struggled to satisfy the growing number of needs. For example, human stem cell technology and CAR-T cell therapy require culture media whose components must be animal component and xenobiotic free, yet retain high activity and scalability.
For human applications and research, a human cell expression system is ideal. All our HumanKine® recombinant proteins are made using HEK293 cells and are perfect for the new needs of medicine.
Products derived from or by an animal are not used at any point during production.
Though CHO and insect cells are eukaryotic, their ability to process human proteins does not match human cells in many cases. For example, Figure 1 shows that human cells generate more mature Activin A dimers than CHO cells.
Glycosylation is crucial to stability and activity. CHO and insect cells have vastly different machinery for this process, producing glycosylated species that can be very different from humans. Figure 2 contains an example where glycosylation differs between expression systems.
Due to native glycosylation and maturation, human cell expressed proteins can outperform other systems in terms of stability. Figure 3 shows how HumanKine FGF has greater stability in culture than an E. coli-derived FGF.
The above features synergize to create proteins that tend to have higher activity than those produced in other expression systems. Figure 4 compares activity for multiple cytokines between eukaryotic systems.
There is a common thread that unites many biotechnology stories: Discover a general principle in bacteria, then work up model organisms until ready to apply to human goals. Protein production follows this pattern and with HumanKine® products, we are finally at the stage of using human cells to make human proteins for human use.
|SDS-PAGE gel with Coomassie blue staining of purified Activin A from CHO cell and HumanKine® systems, demonstrating the formation of mature Activin A dimers.|
|HPLC comparison of glycosylation of human cell expressed (Humanzyme) and CHO EPO, demonstrating significant differences in glycan composition. Fetuin was used as a positive control.|
|Comparison of stability of HumanKine® (FGF basic-TS, red) and E. coli-derived (FGF basic, blue) FGF incubated in cell culture at 37°C without cells.|
|Comparison of activity of insect, human, and E. coli cell expressed cytokines (A, IL1B. B, IL6. C, IL23. D, TGFB1), determined by Th17 differentiation of human CDE4+ cells.|
See below for a full list of HumanKine® products:
|Product Name||Catalog number||Activity spec.||Purity||Citations|
|Activin A||HZ-1138||≤5 ng/mL EC50||>95%||16|
|beta NGF||HZ-1222||≤3 ng/mL EC50||>95%|
|BMP-2||HZ-1128||≤60 ng/mL EC50||>95%||21|
|BMP-4||HZ-1045||≤10 ng/mL EC50||>95%||41|
|BMP-7||HZ-1229||≤100 ng/mL EC50||>95%||6|
|Cystatin C||HZ-1211||≤5 µM IC50||>95%|
|EPO||HZ-1168||≤2.5 ng/mL EC50||>95%||3|
|FGF Basic TS||HZ-1285||≤0.5 ng.mL EC50||>95%||8|
|FGF-4||HZ-1218||≤1.25 ng/mL EC50||>95%|
|FGF-7 (KGF)||HZ-1100||≤7.5 ng/mL EC50||>95%||1|
|FGF-8b||HZ-1103||≤10 ng/mL EC50||>95%||1|
|FLT3 Ligand||HZ-1151||≤0.8 ng/mL EC50||>95%||10|
|G-CSF||HZ-1207||≤0.1 ng/mL EC50||>95%||6|
|GDNF||HZ-1311||≤ 10 ng/mL EC50||>95%|
|GM-CSF||HZ-1002||≤0.5 ng/mL EC50||>95%||10|
|HGF||HZ-1084||≤20 ng/mL EC50||>95%||8|
|HGH||HZ-1007||≤0.5 ng/mL EC50||>95%||2|
|IFN alpha 2A||HZ-1066||≤0.4 ng/mL EC50||>95%||4|
|IFN alpha 2B||HZ-1072||≤0.12 ng/mL EC50||>95%||2|
|IFN beta||HZ-1298||≤0.1 ng/mL EC50||>95%|
|IFN gamma||HZ-1301||≤0.05 ng/mL EC50||>95%||3|
|IL-1 beta||HZ-1164||≤0.05 ng/mL EC50||>95%||16|
|IL-2||HZ-1015||≤5 ng/mL EC50||>95%||5|
|IL-3||HZ-1074||≤2 ng/mL EC50||>95%||10|
|IL-4||HZ-1004||≤0.6 ng/mL EC50||>95%||17|
|IL-6||HZ-1019||≤0.5 ng/mL EC50||>95%||19|
|IL-7||HZ-1281||≤1 ng/mL EC50||>95%|
|IL-9||HZ-1240||≤1 ng/mL EC50||>95%||2|
|IL-10||HZ-1145||≤1.5 ng/mL EC50||>95%|
|IL-12||HZ-1256||≤2 ng/mL EC50||>95%||3|
|IL-17 (IL-17A)||HZ-1113||≤2 ng/mL EC50||>95%||3|
|IL-17F||HZ-1116||≤10 ng/mL EC50||>95%|
|IL-23||HZ-1254||≤4 ng/mL EC50||>95%||11|
|IL-27||HZ-1275||≤12 ng/mL EC50||>95%||1|
|IL-28A||HZ-1235||≤5 ng/mL EC50||>95%||2|
|IL-28B||HZ-1245||≤1 ng/mL EC50||>95%||3|
|IL-29||HZ-1156||≤5 ng/mL EC50||>95%||2|
|Lefty-1||HZ-1109||≤40 ng/mL EC50||>95%||1|
|LIF||HZ-1292||≤0.2 ng/mL EC50||>95%|
|M-CSF||HZ-1192||≤4 ng/mL EC50||>95%||5|
|Noggin||HZ-1118||≤15 ng/mL EC50||>95%||5|
|Oncostatin M||HZ-1030||≤1 ng/mL EC50||>95%
|PDGF-aa||HZ-1215||≤10 ng/mL EC50||>95%|
|PDGFbb||HZ-1308||≤3 ng/mL EC50||>95%||1|
|pro-IGF-II||HZ-1161||≤50 ng/mL EC50||>95%||1|
|SCF||HZ-1024||≤25 ng/mL EC50||>95%||9|
|Sonic Hedgehog (SHH)||HZ-1306||≤350 ng/mL EC50||>90%
|TGF beta 1||HZ-1011||≤0.5 ng/mL EC50||>95%||82|
|TGF beta 2||HZ-1092||≤0.5 ng/mL EC50||>95%||4|
|TGF beta 3||HZ-1090||≤0.5 ng/mL EC50||>95%||8|
|TNF alpha||HZ-1014||≤0.5 ng/mL EC50||>95%||9|
|TPO||HZ-1248||≤5 ng/mL EC50||>95%||2|
|VEGF 121||HZ-1204||≤15 ng/mL EC50||>95%||14|
|VEGF 165||HZ-1038||≤5 ng/mL EC50||>95%||11|
|Wnt3A||HZ-1296||≤20 ng/mL EC50||>90%||1|